Nuvectis Pharma, Inc.
NVCT
NASDAQ·Healthcare·Biotechnology·Mkt cap $649.9M
$24.49
▲ +0.49%
P/E
-18.69
Mkt Cap
$649.9M
52-Wk Range
$5.55–$29.28
52-Week Range
$5.55 - $29.28
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 282.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Novel HSF1 pathway inhibition mechanism with limited competitive landscape
- Dual kinase inhibitor platform targeting c-Src and YES1 pathways
- Precision medicine approach enabling targeted patient populations and potential biomarker-driven development
Bear Case
1 risk
- Low volatility (beta -0.3).
Growth
Stable outlook
Clinical trial advancement and regulatory milestones for NXP800 and NXP900
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+160.0% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying NVCT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 4, 2026
Reported EPS of -$0.30 vs -$0.26 consensus (-14.5% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-14.5%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Cantor Fitzgerald · Aug 24, 2026
vs Industry
How NVCT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related